Carcinoma Squamous Cell
📧 Sign up to get email alerts when something new happens for Carcinoma Squamous Cell.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer [Phase 2]
Phase 2 trial update on de-intensification radiation therapy targeting involved-field in head and neck squamous cell carcinoma; results post…
-
EMA withdrawal · 2021-11-29EMA Application withdrawn: Zynyz (retifanlimab) — Incyte Biosciences Distribution B.V.
The EMA has withdrawn the application for Zynyz (retifanlimab) by Incyte Biosciences Distribution B.V. for anus neoplasms and squamous cell …
-
CLINICAL_TRIALS trial_result · 2021-11-08Clinical Trial Update: A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer [Phase 1, Phase 2]
A Phase I/II study evaluating radiation therapy with paclitaxel poliglumex and cetuximab in advanced head and neck cancer has completed.
-
CLINICAL_TRIALS trial_result · 2019-07-15Clinical Trial Update: Simultaneous Integrated Boost (SIB)- IMRT [Phase 2]
Phase 2 trial update on Simultaneous Integrated Boost IMRT for squamous cell carcinoma, completed.
-
EMA withdrawal · 2009-07-23EMA Application withdrawn: Contusugene Ladenovec Gendux — Gendux Molecular Limited
The EMA withdrawal of the application for Contusugene Ladenovec Gendux by Gendux Molecular Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.